Cancer Immunology, Immunotherapy

, Volume 29, Issue 3, pp 179–184 | Cite as

Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse

  • Philip O. Livingston
  • Gerd Ritter
  • Michele Jones Calves
Original Articles

Summary

The gangliosides GM2, GD2 and GD3 are differentiation antigens expressed on the cell surface of human melanomas and other cancers of neuroectodermal origin. We have compared the antibody response after vaccination with gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse. Purified gangliosides were injected subcutaneously alone or attached to Salmonella minnesota mutant R595 after pretreatment of the mice with low-dose cyclophosphamide. Spontaneous GM1 antibodies, but not antibodies against the other gangliosides, were detected in many mice, the incidence increasing with age. Purified gangliosides injected alone (in saline) induced no antibody response. R595/GM1 and R595/GD3 vaccination induced consistent high-titer antibody responses. R595/GM2 and R595/GD2 induced occasional antibody responses, and R595/GM3 induced no antibody response. Comparison of the antibody responses induced against these gangliosides in the mouse with those in man reveals that GM1, GM3 and GD2 have a similar immunogenicity in both species while the relative immunogenicity of GM2 and GD3 is reversed. To understand better the basis for these differences, the antibody responses against the five gangliosides in man and the mouse were compared with their known expression in normal tissues. No correlation was detected between ganglioside expression in normal brain and immunogenicity, consistent with this being a cloistered site. The antibody responses did correlate inversely with expression in normal non-brain human and murine tissues. Variations between species of ganglioside immunogenicity may reflect variations in ganglioside expression in normal tissues.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ando S, Chang N-C, Yu RK (1978) High-performance thinlayer chromatography and densitometric determination of brain ganglioside compositions of several species. Anal Biochem 89:437–450Google Scholar
  2. 2.
    Brightman MW, Reese TS (1969) Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol 40:648–677Google Scholar
  3. 3.
    Cahan LD, Irie RF, Singh R, Cassidenti A, Paulson JC (1982) Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. Proc Natl Acad Sci USA 79:7629Google Scholar
  4. 4.
    Cheresh DA, Harper JR, Schulz G, Reisfeld RA (1984) Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci USA 81:5767Google Scholar
  5. 5.
    Cheresh DA, Honsik CJ, Staffileno LK, Jung G, Reisfeld RA (1985) Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. Proc Natl Acad Sci USA 82:5155Google Scholar
  6. 6.
    Cheung N-K V, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF (1985) Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 45:2642Google Scholar
  7. 7.
    Cheung N-K V, Lazarus H, Miraldi FD, et al. (1987) Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1430–1440Google Scholar
  8. 8.
    Cordon-Cardo C, Graus F, Andersen N, Houghton A, Cheung NK (1988) Distribution of GD2 ganglioside in the human nervous system detected by a mouse monoclonal antibody: relevance to treatment with anti-ganglioside antibodies. Brain Res (in press)Google Scholar
  9. 9.
    Dippold WG, Lloyd KO, Li LTC, Ikeda H, Oettgen HF, Old LJ (1980) Cell surface antigens of human malignant melanoma. Proc Natl Acad Sci USA 77:6114Google Scholar
  10. 10.
    Ehrlich P (1900) On autoimmunity with special references to cell life. Proc R Soc Lond [Biol] 66B:424–448Google Scholar
  11. 11.
    Endo T, Scott DD, Stewart SS, Kundu SK, Marcus DM (1980) Antibodies to glycosphinogolipids in patients with multiple sclerosis and SLE. J Immunol 132:1793–1797Google Scholar
  12. 12.
    Hamanaka S, Handa S, Yamakawa T (1979) Ganglioside compositions of erythrocytes from various strains of inbred mice. J Biochem (Tokyo) 86:1623Google Scholar
  13. 13.
    Hashimoto Y, Otsuka H, Yamakawa T (1982) The occurrence of GM4 and GM2 in erythrocytes from inbred strains of mice. J Biochem (Tokyo) 91:1039–1046Google Scholar
  14. 14.
    Hashimoto Y, Suzuki A, Yamakawa T, Miyashita N, Moriwaki K (1983) Expression of GM1 and GD1a in mouse liver is linked to the H-2 complex on chromosome 17. J Biochem (Tokyo) 94:2043–2048Google Scholar
  15. 15.
    Hawkes R, Niday E, Gordon J (1982) A dot-immunobinding assay for monoclonal and other antibodies. Anal Biochem 119:142–147Google Scholar
  16. 16.
    Head JR, Billingham RE (1985) Immunologically privileged sites in transplantation immunology and oncology. Perspect Biol Med 29:115–131Google Scholar
  17. 17.
    Herlyn M, Rodeck U, Mancianti M-L, et al. (1987) Expression of melanoma-associated antigens in rapidly dividing human melanocytes in culture. Cancer Res 47:3057–3061Google Scholar
  18. 18.
    Houghton AN, Mintzer D, Cordon-Cardo C, et al. (1985) Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82:1242Google Scholar
  19. 19.
    Iwamori M, Harpin ML, Lachapelle F, Baumann N (1985) Brain gangliosides of quaking and shiverer mutants: qualitative and quantitative changes of monosialogangliosides in the quaking brain. J Neurochem 45:73–78Google Scholar
  20. 20.
    Kawashima I, Tada N, Ikegami S, Nakamura S, Ueda R, Tai T (1988) Mouse monoclonal antibodies detecting disialogangliosides on mouse and human T lymphomas. Int J Cancer 41:267–274Google Scholar
  21. 21.
    Kemp JD, Weinfeld HF, Koerner TAW (1987) A quantitative analysis of H-2 linked effects on hepatic ganglioside composition. Immunogenetics 26:130–137Google Scholar
  22. 22.
    Livingston PO (1989) Experimental and clinical studies with active specific immunotherapy. In: Mitchell MS (ed.) Immunity to cancer II. Liss, New York, pp 309–322Google Scholar
  23. 23.
    Livingston PO, DeLeo AB, Jones M, Oettgen HF, Old LJ (1983) Comparison of approaches for augmenting the serological response to the Meth A antigen. Pretreatment with cyclophosphamide is most effective. J Immunol 131:2601Google Scholar
  24. 24.
    Livingston PO, Jones M, DeLeo AB, Oettgen HF, Old LJ (1985) The serological response to Meth A sarcoma vaccines after cyclophosphamide treatment is further increased by various adjuvants. J Immunol 135:1505–1509Google Scholar
  25. 25.
    Livingston PO, Kaelin E, Pinsky CM, Oettgen HF, Old LJ (1985) IV. Serological response in stage II melanoma patients receiving allogeneic melanoma cell vaccines. Cancer 56:2194–2220Google Scholar
  26. 26.
    Livingston PO, Jones Calves M, Natoli EJ Jr (1987) Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: Purified GM2 is superior to whole cells. J Immunol 138:1524–1529Google Scholar
  27. 27.
    Livingston PO, Natoli EJ Jr, Jones Calves M, Stockert E, Oettgen HF, Old LJ (1987) Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 84:2911–2915Google Scholar
  28. 28.
    Mahadik S, Laev H, Rapport MM (1986) Preparation and specificity of 11 monoclonal antibodies to GM1 ganglioside. J Neurochem 47:1172–1175Google Scholar
  29. 29.
    Milgrom F. Allotransplantation and autoimmunity (1980) Transplant Proc 12:557–565Google Scholar
  30. 30.
    Miyake M, Ito M, Hitomi S, et al. (1988) Generation of two murine monoclonal antibodies that can discriminate N-glycolyl and N-acetyl neuraminic acid residues of GM2 gangliosides. Cancer Res 48:6154–6160Google Scholar
  31. 31.
    Nakabayashi H, Iwamori M, Nagai Y (1984) Analysis and quantitation of gangliosides as p-bromophenacyl derivatives by high-performance liquid chromatography. J Biochem (Tokyo) 96:977–984Google Scholar
  32. 32.
    Nakamura K, Hashimoto Y, Yamakawa T, Suzuki A (1988) Genetic polymorphism of ganglioside expression in mouse organs. J Biochem (Tokyo) 103:201–208Google Scholar
  33. 33.
    Natoli EJ Jr, Livingston PO, Cordon-Cardo C, et al. (1986) A murine monoclonal antibody detecting N-acetyl and N-glycolyl GM2: characterization of cell surface reactivity. Cancer Res 46:4116–4120Google Scholar
  34. 34.
    Nilsson O, Svennerholm L (1982) Characterization and quantitative determination of gangliosides and neutral glycosphingolipids in human liver. J Lipid Res 23:327–334Google Scholar
  35. 35.
    Nores GA, Dohi T, Taniguchi M, Hakomori S-I (1987) Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen. J Immunol 139:3171–3176Google Scholar
  36. 36.
    Nudelman ES, Hakomori S, Kannagi R, Levery S, Yeh M-H, Hellstrom KE, Hellstrom I (1982) Characterization of a human melanoma-associated antigen defined by a monoclonal antibody, 4.2. J Biol chem 257:12752Google Scholar
  37. 37.
    Portoukalian J, Zwingelstein N A-M, Dore J-F (1978) Alteration of gangliosides in plasma and red cells of humans bearing melanoma tumors. Biochem Biophys Commun 85:916–920Google Scholar
  38. 38.
    Rauvala H (1976) Isolation and partial characterization of human kidney gangliosides. Biochim Biophys Acta 424:284–295Google Scholar
  39. 39.
    Real FX, Houghton AN, Albino AP, Cordon-Cardo C, Melamed MR, Oettgen HF, Old LJ (1985) Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. Cancer Res 45:4401–4411Google Scholar
  40. 40.
    Richards RL, Alving CR (1980) Immune reactivities of antibodies against glycolipids. Am Cancer Soc 27:461–473Google Scholar
  41. 41.
    Rose NR (1981) Autoimmune diseases. Sci Am 244:80–103Google Scholar
  42. 42.
    Seyfried TN, Glaser GH, Yu RK (1979) Genetic variability for regional brain gangliosides in five strains of young mice. Biochem Genet 17:43Google Scholar
  43. 43.
    Svennerholm L (1963) Chromatographic separation of human brain gangliosides. J Neurochem 10:613–623Google Scholar
  44. 44.
    Tai T, Cahan LD, Tsuchida T, Saxton RE, Irie RF, Morton DL (1985) Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 35:607Google Scholar
  45. 45.
    Taniguchi M, Wakabayashi S (1984) Shared antigenic determinant expressed on various mammalian melanoma cells: Gan 75:418Google Scholar
  46. 46.
    Towbin H, Schoenenberger C, Ball R, Braun DG, Roselfelder G (1984) Glycosphingolipid-blotting: an immunological detection procedure after separation by thin layer chromatography. J Immunol Methods 72:471–479Google Scholar
  47. 47.
    Tsuchida T, Saxton RE, Irie RF (1987) Gangliosides of human melanoma: GM2 and tumorigenicity. J Natl Cancer Inst 78:55–59Google Scholar
  48. 48.
    Welte K, Miller G, Chapman PB, Natoli E, Kunicka JE, Cordon-Cardo C, Old LJ, Houghton AN (1987) Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. J Immunol 139:1763–1771Google Scholar
  49. 49.
    Werkmeister JA, Triglia T, Mackay IR, Dowling JP, Varigos GA, Morstyn G, Burns GF (1987) Fluctuations in the expression of a glycolipid antigen associated with differentiation of melanoma cells monitored by a monoclonal antibody. Leo Mel 31. Cancer Res 47:225–230Google Scholar
  50. 50.
    Wiegandt H (1973) Gangliosides of extraneural organs. Hoppe-Seyler's Z Physiol Chem 354:1049–1056Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • Philip O. Livingston
    • 1
  • Gerd Ritter
    • 1
  • Michele Jones Calves
    • 1
  1. 1.The Memorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations